Canada Markets open in 1 hr 18 mins

Rakovina Therapeutics Inc. (RKV.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.1300-0.0150 (-10.34%)
At close: 03:54PM EST
Full screen
Previous Close0.1450
Open0.1300
Bid0.1250 x N/A
Ask0.1300 x N/A
Day's Range0.1300 - 0.1300
52 Week Range0.1000 - 0.2500
Volume35,500
Avg. Volume15,305
Market Cap9.075M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Rakovina Therapeutics Announces Presentation at the 6th Annual DDR-inhibitors Summit

    VANCOUVER, British Columbia, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), is pleased to announce a scientific presentation at the 6th Annual DDR Inhibitors Summit in Boston, MA. The 6th Annual DDR Inhibitors Summit, held in Boston January 24-26, 2023, brought together academic and pharmaceutical industry researchers to share progress across the preclinical and clinical DDR inhibitor landscape. The conference aims to provide an up-to-date overview of

  • GlobeNewswire

    Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022

    VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response (DDR) technologies, is pleased to announce that it has been invited to present at the Emerging Growth Conference on Wednesday, November 30, 2022, at 10:15am Eastern standard time. Rakovina invites individual and institutional investors as well as advisors and

  • GlobeNewswire

    Rakovina Therapeutics Inc. Announces Q3 2022 Financial Results and Provides Corporate Update

    VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for the quarter ended September 30, 2022 and provided a corporate update. Corporate Update Rakovina Therapeutics has continued to communicate progress in the Company’s research and development programs through presentations at pee